MetLife Investment Advisors LLC Takes Position in Clovis Oncology (CLVS)

MetLife Investment Advisors LLC acquired a new position in shares of Clovis Oncology (NASDAQ:CLVS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,203 shares of the biopharmaceutical company’s stock, valued at approximately $1,374,000.

Other institutional investors also recently made changes to their positions in the company. First Republic Investment Management Inc. acquired a new position in shares of Clovis Oncology during the third quarter worth about $251,000. BB&T Securities LLC acquired a new position in shares of Clovis Oncology during the third quarter worth about $288,000. Greenwood Capital Associates LLC grew its position in shares of Clovis Oncology by 21.6% during the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 996 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its position in shares of Clovis Oncology by 30.1% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 6,376 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 1,476 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new position in shares of Clovis Oncology during the fourth quarter worth about $490,000.

How to Become a New Pot Stock Millionaire

CLVS stock opened at $55.52 on Monday. The company has a market cap of $2,807.81, a P/E ratio of -10.84 and a beta of 0.93. Clovis Oncology has a fifty-two week low of $45.42 and a fifty-two week high of $99.45. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.25. The firm had revenue of $17.04 million during the quarter, compared to analysts’ expectations of $19.42 million. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm’s revenue was up 21746.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.83) earnings per share. sell-side analysts anticipate that Clovis Oncology will post -4.85 earnings per share for the current fiscal year.

In related news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $61.47, for a total transaction of $276,615.00. Following the completion of the sale, the director now owns 12,118 shares in the company, valued at $744,893.46. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the sale, the insider now owns 180,571 shares of the company’s stock, valued at approximately $9,767,085.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,000 shares of company stock valued at $886,365. 12.50% of the stock is owned by company insiders.

A number of brokerages have recently commented on CLVS. BidaskClub downgraded Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday, February 9th. JPMorgan Chase reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. SunTrust Banks lowered their price objective on Clovis Oncology from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, February 27th. Finally, Credit Suisse Group set a $86.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $88.57.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/09/metlife-investment-advisors-llc-takes-position-in-clovis-oncology-clvs.html.

Clovis Oncology Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply